✍ Scribed by S.M. Okarvi
No coin nor oath required. For personal study only.
An Erratum has been published for this article in Medicinal Research Reviews 2004;24:685–686.
Small synthetic receptor‐binding peptides are the agents of choice for diagnostic imaging and radiotherapy of cancers due to their favorable pharmacokinetics. Molecular modification techniques permit the synthesis of a variety of bioactive peptides with chelating groups, without compromising biological properties. Various techniques have been developed that allow efficient and site‐specific labeling of peptides with clinically useful radionuclides such as ^99m^Tc, ^123^I, ^111^In, and ^18^F. Among them, ^99m^Tc is the radionuclide of choice because of its excellent chemical and imaging characteristics. Recently, many ^99m^Tc‐labeled peptides have proven to be useful imaging agents. Beside ^99m^Tc‐labeled peptides, several peptides radiolabeled with ^111^In and ^123^I have been prepared and characterized. In addition, ^18^F‐labeled peptides hold clinical potential due to their ability to quantitatively detect and characterize a variety of human diseases using positron‐emission tomography. The availability of this wide range of peptides labeled with different radionuclides offers multiple diagnostic and therapeutic applications. Various receptors are over‐expressed in particular tumor types and peptides binding to these receptors can be used to visualize tumor lesions scintigraphically. Thus, radiolabeled peptides have potential use as carriers for the delivery of radionuclides to tumors, infarcts, and infected tissues for diagnostic imaging and radiotherapy. Many radiolabeled peptides are currently under investigation to determine their potential as imaging agents. These peptides are designed mainly for thrombus, tumor, and infection/inflammation imaging. This article presents recent developments in small synthetic peptides for imaging of thrombosis, tumors, and infection/inflammation. © 2004 Wiley Periodicals, Inc. Med Res Rev, 24, No. 3, 357–397, 2004
📜 SIMILAR VOLUMES
## Abstract The original article to which this Erratum refers was published in Med Res Rev, 24, No. 3, 357‐397, 2004 No abstract
A simple enzyme immunoassay has been developed based on measuring antibodies to synthetic peptides corresponding to sequences in the Epstein-Barr nuclear antigen (EBNA). This assay, which is repro-ducible, quantitative, and simple to perform and interpret, can be an effective tool to aid in the diag